

Thomas Nyström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4053607/publications.pdf>

Version: 2024-02-01

90
papers

3,860
citations

147566

31
h-index

128067

60
g-index

92
all docs

92
docs citations

92
times ranked

5147
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E1209-E1215.	1.8	583
2	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 379.	3.8	520
3	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 709-717.	5.5	285
4	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 344-351.	2.2	164
5	Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. <i>Regulatory Peptides</i> , 2005, 125, 173-177.	1.9	161
6	Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. <i>Diabetologia</i> , 2016, 59, 1692-1701.	2.9	93
7	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 274-284.	2.4	88
8	Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. <i>Diabetologia</i> , 2012, 55, 926-935.	2.9	87
9	Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization. <i>PLoS ONE</i> , 2014, 9, e103114.	1.1	80
10	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 831-841.	2.2	75
11	Inorganic nitrite stimulates pancreatic islet blood flow and insulin secretion. <i>Free Radical Biology and Medicine</i> , 2012, 53, 1017-1023.	1.3	74
12	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 39-47.	1.1	68
13	The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance. <i>Hormone and Metabolic Research</i> , 2008, 40, 593-606.	0.7	64
14	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1136-1145.	2.2	61
15	Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. <i>Journal of Molecular Endocrinology</i> , 2013, 50, 229-241.	1.1	58
16	Long-Term Prognosis in Patients With Type 1 and 2 Diabetes Mellitus After Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1644-1652.	1.2	58
17	Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 556-563.	2.2	58
18	Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E919-E925.	1.8	56

#	ARTICLE	IF	CITATIONS
19	The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1 β /CXCR4 pathway. <i>Cardiovascular Diabetology</i> , 2018, 17, 60.	2.7	46
20	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 199-208.	1.1	44
21	Increased levels of tumour necrosis factor- α (TNF- α) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. <i>Clinical Science</i> , 2006, 110, 673-681.	1.8	43
22	Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium. <i>Molecular and Cellular Endocrinology</i> , 2009, 297, 112-126.	1.6	40
23	Antidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 15-25.	1.2	40
24	Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2015, 66, 535-543.	1.2	39
25	Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. <i>Cardiovascular Diabetology</i> , 2014, 13, 152.	2.7	37
26	Cliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 537-541.	2.2	37
27	Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin. <i>Acta Neuropathologica Communications</i> , 2018, 6, 14.	2.4	37
28	Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 70.	1.2	35
29	Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 718-723.	2.4	35
30	Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy. <i>Clinical Endocrinology</i> , 2015, 83, 28-35.	1.2	34
31	Insulin sensitivity and beta-cell function after carbohydrate oral loading in hip replacement surgery: A double-blind, randomised controlled clinical trial. <i>Clinical Nutrition</i> , 2014, 33, 392-398.	2.3	33
32	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. <i>International Journal of Cardiology</i> , 2016, 202, 291-296.	0.8	33
33	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. <i>Diabetes Care</i> , 2021, 44, 1211-1218.	4.3	32
34	Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. <i>Neuropharmacology</i> , 2018, 136, 280-286.	2.0	30
35	Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. <i>Clinical Science</i> , 2005, 108, 121-128.	1.8	26
36	C-reactive protein: a marker or a player?. <i>Clinical Science</i> , 2007, 113, 79-81.	1.8	26

#	ARTICLE	IF	CITATIONS
37	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00036.	1.0	24
38	Risk of first stroke in people with type 2 diabetes and its relation to glycaemic control: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 182-190.	2.2	24
39	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1890-1901.	0.8	24
40	Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. <i>Regulatory Peptides</i> , 2014, 190-191, 25-31.	1.9	23
41	Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. <i>Oncotarget</i> , 2016, 7, 5865-5876.	0.8	23
42	Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long-term follow-up study. <i>Diabetologia</i> , 2014, 57, 1703-1710.	2.9	21
43	PCI Versus CABG in Patients With Type 2 Diabetes and Multivessel Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1441-1451.	1.2	21
44	Obesity-induced type 2 diabetes impairs neurological recovery after stroke in correlation with decreased neurogenesis and persistent atrophy of parvalbumin-positive interneurons. <i>Clinical Science</i> , 2019, 133, 1367-1386.	1.8	21
45	Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4. <i>Bioscience Reports</i> , 2016, 36, .	1.1	20
46	Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 202.	2.7	19
47	Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. <i>Cardiovascular Diabetology</i> , 2012, 11, 27.	2.7	18
48	Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study. <i>Frontiers in Endocrinology</i> , 2017, 8, 325.	1.5	17
49	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000602.	1.2	17
50	Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery. <i>Diabetes</i> , 2020, 69, 1961-1973.	0.3	16
51	Estimated glucose disposal rate and long-term survival in type 2 diabetes after coronary artery bypass grafting. <i>Heart and Vessels</i> , 2017, 32, 269-278.	0.5	15
52	Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 493.	1.1	15
53	Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. <i>Journal of Internal Medicine</i> , 2002, 252, 570-574.	2.7	14
54	Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 5.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014. <i>PharmacoEconomics - Open</i> , 2018, 2, 393-402.	0.9	14
56	Western Diet Accelerates the Impairment of Odor-Related Learning and Olfactory Memory in the Mouse. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3590-3602.	1.7	14
57	Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme. <i>Oncotarget</i> , 2016, 7, 79572-79583.	0.8	14
58	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. <i>Cardiovascular Diabetology</i> , 2021, 20, 237.	2.7	14
59	Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging. <i>Neurobiology of Aging</i> , 2020, 89, 12-23.	1.5	13
60	Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. <i>British Journal of Pharmacology</i> , 2022, 179, 677-694.	2.7	12
61	Type 2 diabetes alters hippocampal gamma oscillations: A potential mechanism behind impaired cognition. <i>Psychoneuroendocrinology</i> , 2017, 82, 46-50.	1.3	10
62	Dapagliflozin vs non-SGLT2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2651-2659.	2.2	10
63	LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study. <i>Journal of Internal Medicine</i> , 2021, 289, 873-886.	2.7	10
64	Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	9
65	The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 619-630.	2.2	9
66	Sex, Diastolic Blood Pressure, and Outcome after Thrombolysis for Ischemic Stroke. <i>Stroke Research and Treatment</i> , 2014, 2014, 1-7.	0.5	8
67	Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel-group study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00058.	1.0	8
68	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 11561.	1.6	8
69	Role of Prolactin Receptors in Lymphangiomyomatosis. <i>PLoS ONE</i> , 2016, 11, e0146653.	1.1	8
70	Pituitary Adenylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieu. <i>PLoS ONE</i> , 2016, 11, e0156867.	1.1	8
71	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. <i>Diabetes Care</i> , 2019, 42, 2032-2041.	4.3	7
72	Reduced expression of OXPHOS and DNA damage genes is linked to protection from microvascular complications in long-term type 1 diabetes: the PROLONG study. <i>Scientific Reports</i> , 2021, 11, 20735.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. <i>International Journal of Cardiology</i> , 2021, 330, 23-29.	0.8	6
74	Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors. <i>PLoS ONE</i> , 2021, 16, e0254079.	1.1	6
75	Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 346-355.	2.3	5
76	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6â€“10. <i>Diabetes Care</i> , 2018, 41, e104-e105.	4.3	5
77	The Stroke-Induced Increase of Somatostatin-Expressing Neurons is Inhibited by Diabetes: A Potential Mechanism at the Basis of Impaired Stroke Recovery. <i>Cellular and Molecular Neurobiology</i> , 2021, 41, 591-603.	1.7	5
78	Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke. <i>Cardiovascular Diabetology</i> , 2021, 20, 240.	2.7	5
79	Increased Plasma Soluble Interleukin-2 Receptor Alpha Levels in Patients With Long-Term Type 1 Diabetes With Vascular Complications Associated With IL2RA and PTPN2 Gene Polymorphisms. <i>Frontiers in Endocrinology</i> , 2020, 11, 575469.	1.5	4
80	Risk factors for nephropathy in persons with type 1 diabetes: a population-based study. <i>Acta Diabetologica</i> , 2022, , 1.	1.2	3
81	Earlier intensified insulin treatment of Type 1 diabetes and its association with long-term macrovascular and renal complications. <i>Diabetic Medicine</i> , 2016, 33, 463-470.	1.2	2
82	Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2380-2382.	1.6	2
83	Early and long-term prognosis in patients with and without type 2 diabetes after carotid intervention: a Swedish nationwide propensity score matched cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 85.	2.7	2
84	A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarius: an Effect that is Partially Reversed by Drugs Normalizing Glycemia. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 1995-2002.	1.7	2
85	Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8). <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 89-98.	1.3	2
86	Dapagliflozin Is Associated With Lower Risk Of Hospitalization For Kidney Disease, Heart Failure And All Cause Death Compared To DPP-4i: CVD-REAL Nordic. <i>Canadian Journal of Diabetes</i> , 2017, 41, S51.	0.4	1
87	P6400 Risk for heart failure after acute myocardial infarction, a nationwide report on 73 303 patients with and without diabetes 2012â€“2017 in the SWEDEHEART-SCAAR registry. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
88	Abstract 515: Effects of the Glucagon-Like Peptide-1 Analog Exendin-4 on Reendothelialization and Intimal Hyperplasia Formation in an Animal Model of Vascular Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	1.1	0
89	Abstract 476: Glucagon Like Peptide -1 Receptor Activation Does Not Affect Re-endothelialization But Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Non-diabetic Model of Arterial Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0
90	Abstract 17564: Long-term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. <i>Circulation</i> , 2015, 132, .	1.6	0